General HIV Studies
| |
Comparative
efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in
combination
with efavirenz: results of a systematic overview.
Bartlett JA, Chen SS,
Quinn JB.
HIV Clin Trials. 2007 Jul-Aug;8(4):221-6.
Abstract
A WEEK-IN-REVIEW FEATURED REPORT
Comparative
efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in
combination
with efavirenz: results of a systematic overview.
Bartlett JA, Chen SS, Quinn JB.
HIV Clin Trials. 2007 Jul-Aug;8(4):221-6.
Abstract
Comparison of the effectiveness of initial combined antiretroviral
therapy with nelfinavir or
efavirenz at a university-based outpatient service in
Brazil.
Vanni T, Morejón KM, Santana RC, et al
Braz J Med Biol Res. 2007 Jul;40(7):963-9.
Abstract
|
A WEEK-IN-REVIEW FEATURED
REPORT
Plasma HIV-1 RNA Dynamics in Antiretroviral-Naive Subjects
Receiving either Triple-Nucleoside
or Efavirenz-Containing Regimens: ACTG A5166s
Kuritzkes DR, Ribaudo HJ, Squires KE, et al
J Infect Dis. 2007 Apr 15;195(8):1169-76.
Abstract
|
A WEEK-IN-REVIEW FEATURED REPORT
Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose
combination: first-line
therapy for all?
Goicoechea M, Best B.
Expert Opin Pharmacother. 2007 Feb;8(3):371-82
Abstract
|
A WEEK-IN-REVIEW FEATURED REPORT
A Comparison between Abacavir and Efavirenz as the Third Drug
Used in Combination with a
Background Therapy Regimen of 2 Nucleoside Reverse-Transcriptase
Inhibitors in Patients with
Initially Suppressed Viral Loads.
Cozzi-Lepri A, Luca AD, Phillips AN, et al
J Infect Dis. 2006 Jul 1;194(1):20-8.
Abstract
|
|
|
|
|
| |
A prospective comparison of the two main indications of efavirenz in 2001
highly active
antiretroviral
therapy (HAART) regimens: first-line versus
salvage use.
Manfredi R, Calza L, Chiodo F.
J Antimicrob Chemother 2002 May;49(5):723-9
Abstract
Evaluation of an
efavirenz-containing regimen: an open-label, multicenter study.
Hartmann M, Rump A, Brust
J, et al
HIV
Clin Trials 2001 Sep-Oct;2(5):421-8
Abstract
Efavirenz as a substitute for protease inhibitors in hiv-1-infected patients
with
undetectable
plasma viral load on haart: a median follow-up of 64 weeks.
Rey D, Schmitt MP, Partisani M, et al.
J Acquir Immune Defic Syndr 2001 Aug 15;27(5):459-62
Abstract
Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV
infection.
Albrecht MA, Bosch RJ, Hammer SM, et al;
N
Engl J Med 2001 Aug 9;345(6):398-407
Abstract
Response to first protease inhibitor- and efavirenz-containing antiretroviral
combination therapy
The Swiss HIV Cohort Study.
Friedl AC, Ledergerber B, Flepp M, et al
AIDS 2001 Sep 28;15(14):1793-1800
Abstract
Comparison of initial combination antiretroviral therapy with a single protease
inhibitor, ritonavir
and saquinavir, or efavirenz.
Lucas GM, Chaisson RE,
Moore RD.
AIDS 2001 Sep 7;15(13):1679-1686
Abstract
|
|
| |
Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir
therapy.
Saah AJ, Haas DW, DiNubile MJ, et al.
J Infect Dis 2003 Apr 1;187(7):1157-62
Abstract |
|
|
| |
Switching from protease inhibitors to efavirenz:
differences in efficacy and tolerance
among risk
groups:a case-control study from the Swiss HIV Cohort,
Hirschel B, Flepp M, Bucher HC, et al .
AIDS 2002 Feb 15;16(3):381-385
Abstract |
|
|
| |
Virological, immunological, and clinical impact of switching from protease
inhibitors to
nevirapine
or to
efavirenz
in patients with human immunodeficiency virus infection and
long-lasting
viral suppression.
Negredo E, Cruz L,
Paredes R, Ruiz L, et al.
Clin Infect Dis 2002 Feb
15;34(4):504-10
Abstract
|
|
|
| |
Switch to
efavirenz in a protease inhibitor-containing regimen.
Knechten H, Sturner KH, Hohn C,
Braun P.
HIV Clin Trials 2001 May-Jun;2(3):200-4
Abstract
|
|
General;
Reports
Treatment
Strategies
Drug
Failure
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader